Podcast Episodes
Back to Search
Portfolio podcast | Five key factors to keep in mind while investing
When one thinks of investing, they may look at a variety of options like opening a fixed deposit account, investing in the shares of a big company su…
4 years, 3 months ago
Are you familiar with the different routes to investing in US stocks?
Since market regulator SEBI has placed restrictions on fresh investments in international mutual funds, investors who may want to average their holdi…
4 years, 3 months ago
Explained: Twitter, India and controversies
Twitter is back in the news for its clash with the Indian government. When the Indian governments claims that Twitter has not removed the tweets that…
4 years, 3 months ago
Will global central banks step in to calm markets sometime?
Kumar Shankar Roy and Hari Viswanath discuss the road ahead for markets and whether or not central banks can provide solace sometime in the near futu…
4 years, 3 months ago
An Unfiltered Tour of Creativity At Cannes
Dentsu Creative India’s chiefs Amit Wadhwa and Ajay Gahlaut talk to Business Line’s Chitra Narayanan about their historic outing at Cannes, the Frenc…
4 years, 4 months ago
Countering Russia, China dominate G7 meet
In the recently concluded G-7 summit, the leaders talked about several issues, but the Russian war in Ukraine and China were the main focal points. I…
4 years, 4 months ago
Why should you take MF nomination seriously
As of March 2021, the amount lying unclaimed with mutual funds was a whopping ₹ 1,590 crore. To address this issue, market regulator SEBI recently ca…
4 years, 4 months ago
Why Congress' Manish Tewari Supports Modi's Agnipath
The Modi government's decision to reform the recruitment process for the armed forces has come under immense criticism. Under the scheme, named Agnip…
4 years, 4 months ago
Intel’s AI skilling journey in India
Intel has been betting big on artificial intelligence (AI) to transform lives across societies and has set itself the target of working with 30,000 i…
4 years, 4 months ago
Why India-focussed pharma stocks are a safer bet?
US generics revenues generated 0.3 per cent CAGR in FY17-22 compared to 11 per cent CAGR in India and emerging markets. As a result, Nifty Pharma ind…
4 years, 4 months ago